Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics

Annals of Internal Medicine

Volumn 132, Issue 10, 2000, Pages 769-779

  Prosser, Lisa A ^b   Stinnett, Aaron A ^c   Goldman, Paula A ^a   Williams, Lawrence W ^a   Hunink, Maria G M ^d   Goldman, Lee ^e   Weinstein, Milton C ^a  

^a HARVARD CENTER FOR RISK ANALYSIS   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIET RESTRICTION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 0034674047     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-10-200005160-00002     Document Type: Article

References (56)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-9.
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001-9.
4. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-57.
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/ Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22.
6. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition of primary and secondary prevention of coronary heart disease. JAMA. 1991;265:1145-51
7. Hay JW, Wittels EH, Gotto AM Jr. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol. 1991;67:789-96.
8. Stinnett AA, Mittleman MA, Weinstein MC, Kuntz KM, Cohen DJ, Williams LW, et al. Appendix C: the cost-effectiveness of dietary and pharmacologic therapy for cholesterol reduction in adults. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
9. Martens LL, Guibert RG. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther. 1994;16:1052-62.
10. Riviere M, Wang S, Leclerc C, Fetzsimon C, Tretiak R. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. CMAJ. 1997;156:991-7.
11. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997,336:332-6.
12. Jacobson TA. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. Am J Cardiol. 1996;78(Suppl 6A):32-41.
13. Ashraf T, Hay JW, Pitt B, Wittels E, Crouse J, Davidson M, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996;78:409-14.
14. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. JAMA. 1995;273: 1032-8.
15. Schulman KA, Kinosian B, Jacobsen TA, Glick H, Willian MK, Koffer H, et al. Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA. 1990;264:3025-33.
16. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 1993;269:3015-23.
17. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health. 1987;77:1417-26.
18. Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA. 1997;277:535-42.
19. Morris S. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Econ. 1997;6:589-601.
20. Denke MA. Individual responsiveness to a cholesterol-lowering diet in post-menopausal women with moderate hypercholesterolemia. Arch Intern Med. 1994;154:1977-82.
21. Denke MA, Grundy SM. Individual responses to a cholesterol-lowering diet in 50 men with moderate hypercholesterolemia. Arch intern Med. 1994;154: 317-25.
22. Denke MA, Grundy SM. Efficacy of low-dose cholesterol-lowering drug therapy in men with moderate hypercholesterolemia. Arch Intern Med. 1995; 155:393-9.
23. Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med. 1991;325:461-6.
24. Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang ZQ, Ripsin CM. Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991;151:1424-32.
25. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-40.
26. Salonen R, Nyyssonen K, Porkkala E, Rummukainen J, Beider R, Park JS, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation. 1995;92:1758-64.
27. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
28. Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation. 1996;94:957-65.
29. Guadagnoli E, Hauptman PJ, Ayanian JZ, Pashos CL, McNeil BJ, Cleary PD. Variation in the use of cardiac procedures after acute myocardial infarction. N Engl J Med. 1995;333:573-8.
30. Drug Topics Red Book. Montvale, NJ: Medical Economics; 1997.
31. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV. Am J Cardiol. 1990;66:22B-30B.
32. Health Care Financing Administration. Physician fee schedule conversion factors. Federal Register. 1996;61:59717.
33. The McGraw-Hill Complete RBRVS. New York McGraw-Hill; 1995.
34. Cornelius L, Beauregard K, Cohen J. Usual Sources of Medical Care and Their Characteristics. National Medical Expenditure Survey Research Findings 11. AHCPR Publication No. 91-00042. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service.
35. Labor Force Statistics from the Current Population Survey. Available at http:// stats.bls.gov/news.release/wkyeng.t02.htm. Accessed 11 July 1997.
36. 1997 Medicare Clinical Laboratory Fee Schedule. Camp Hill, PA: Xact Medicare Services; 1996.
37. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Am J Cardiol. 1993;72:1031-7.
38. Jones PH, Farmer JA, Cressman MD, McKenney JM, Wright JT, Proctor JD, et al. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol. 1991;14:146-51.
39. Crouse JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 1995;75:455-9.
40. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
41. Tsalamandris C, Panagiotopoulos S, Sinha A, Cooper ME, Jerums G. Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients. J Cardiovasc Risk. 1994;1:231-9.
42. Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med. 1994;154:1586-95.
43. Vacek JL, Dittmeier G, Chiarelli T, White J, Bell HH. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 mg) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol. 1995;76:182-4
44. Brown WV. Niacin for lipid disorders. Indications, effectiveness, and safety. Postgrad Med. 1995;98:185-89.
45. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125-31.
46. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism. 1985;34:642-50.
47. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ. 1998;316:1213-20.
48. Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line? In Sloan FA, ed. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceutical and Other Medical Technologies. New York: Cambridge Univ Pr; 1995.
49. Graham JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health. 1998;19:125-52.
50. Avins AL, Browner WS. Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels: what a difference a decade makes. JAMA. 1998;279:445-9.
51. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
52. Myers RH, Kiely DK, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J. 1990;120:963-9.
53. Guibert R, Contandriopoulos AP, Champagne F, Laurier C, Tessier G. Cost-effectiveness analysis of lipid modulators in Canada: results and potential usefulness [Editorial]. Can J Cardiol. 1993;9:28D-29D.
54. Hjalte K, Lindgren B, Persson U. Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden. Pharmacoeconomics. 1992;1:213-6.
55. Martens LL, Ruttens FF, Erkelens DW, Ascoop CA. Cost-effectiveness of cholesterol-lowering therapy in The Netherlands. Simvastatin vs cholestyramine. Am J Med. 1989;87(Suppl 4A):54S-58S.
56. Taylor WC, Pass TM, Shepard DS, Komaroff AL. Cost-effectiveness of cholesterol reduction for the primary prevention of coronary heart disease in men. In: Goldbloom RB, Lawrence RS, eds. Preventing Disease: Beyond the Rhetoric. New York: Springer-Verlag; 1990:437-41.